Carcinogen Hazard Assessment Monographs Program (CHAMP) (R01 Clinical Trial Not Allowed)
Can you apply?
This grant is for academic researchers, research institutions, and nonprofit organizations conducting investigative research related to carcinogenic hazard assessment. Applicants must be eligible for NIH R01 funding mechanisms, though clinical trials are explicitly not allowed. The program supports basic science, preclinical, and epidemiological research aimed at systematically evaluating evidence on potentially carcinogenic substances. Eligible recipients include universities, medical schools, research institutes, independent research organizations, and other domestic institutions with 501(c)(3) status or equivalent. The scope is national, with no geographic restrictions. Supported activities include literature synthesis, hazard characterization, mechanism of action studies, and meta-analyses examining cancer risk from various exposures. Federal facilities may also be eligible under specific circumstances.
Key dates
- Nov 21, 2025 Applications open
- Jun 30, 2026 Application deadline in 29 days
- Oct 1, 2026 Award announced
- Oct 1, 2026 Project start
This grant is for academic researchers, research institutions, and nonprofit organizations conducting investigative research related to carcinogenic hazard assessment. Applicants must be eligible for NIH R01 funding mechanisms, though clinical trials are explicitly not allowed. The program supports basic science, preclinical, and epidemiological research aimed at systematically evaluating evidence on potentially carcinogenic substances. Eligible recipients include universities, medical schools, research institutes, independent research organizations, and other domestic institutions with 501(c)(3) status or equivalent. The scope is national, with no geographic restrictions. Supported activities include literature synthesis, hazard characterization, mechanism of action studies, and meta-analyses examining cancer risk from various exposures. Federal facilities may also be eligible under specific circumstances.
Program description
Through this Notice of Funding Opportunity (NOFO), the National Cancer Institute (NCI) invites applications to critically and systematically evaluate the scientific evidence on carcinogenic hazards to humans. Identifying potential carcinogens is essential for guiding and advancing cancer research, as well as informing cancer control and prevention efforts. The resulting monographs will serve as crucial references that shape health policy and regulation, ultimately helping to reduce the cancer burden for all
Who can apply
Eligible applicants
- 501(c)(3) Public Charity
- Colleges (all higher ed)
- County Government
- Nonprofits
- Private University
- Public Authority
- Public K-12 School
- Public University
- Small Business (SBA-defined)
- Tribal Nation
- Tribal Organization
Details
This grant is for academic researchers, research institutions, and nonprofit organizations conducting investigative research related to carcinogenic hazard assessment. Applicants must be eligible for NIH R01 funding mechanisms, though clinical trials are explicitly not allowed. The program supports basic science, preclinical, and epidemiological research aimed at systematically evaluating evidence on potentially carcinogenic substances. Eligible recipients include universities, medical schools, research institutes, independent research organizations, and other domestic institutions with 501(c)(3) status or equivalent. The scope is national, with no geographic restrictions. Supported activities include literature synthesis, hazard characterization, mechanism of action studies, and meta-analyses examining cancer risk from various exposures. Federal facilities may also be eligible under specific circumstances.
How to apply
Application links
Key dates & requirements
Required documents
- SF-424 (R&R) form and associated NIH forms
- Project narrative (typically 15 pages maximum for R01)
- Detailed research plan with aims, background, and methods
- Budget and budget justification
- Biographical sketches of key personnel (NIH format)
- Current and pending support documentation
- Letters of support from collaborating institutions
- Research strategy including preliminary data
- Human subjects protections documentation (if applicable)
- Animal care protocols (if applicable)
Program contact
- 👤 Tram Kim Lam, PhD, MPH
- 📧 lamt@mail.nih.gov
- 📞 240 276-6967
Funding track record
Recent awards under CFDA 93.399 from the last 3 years — real organizations that won funding through this same program.
Top 10 Largest Recent Awards
-
$22,629,848
-
$20,187,190
-
$19,625,661
-
$19,227,026
-
$18,138,327
-
$17,827,646
-
$17,614,587
-
$16,535,118
-
$16,126,587
-
$14,347,054
Top States by Funding
- NY 7 awards $57.6M
- SC 3 awards $46.6M
- DE 3 awards $43.2M
- IL 3 awards $38.4M
- WI 3 awards $37.9M
Source: USAspending.gov — federal spending transparency. Data covers last 3 years.
FAQ
Am I eligible to apply if my organization is for-profit?
Generally no. NIH R01 grants require 501(c)(3) nonprofit status or equivalent. However, some small businesses and for-profit entities may be eligible under specific programs; contact the NIH grants office to confirm.
Can my research include human clinical trials?
No. This program explicitly excludes clinical trial research. If your work involves intervention testing in human subjects, this is not the right mechanism.
What types of research are supported?
Hazard assessment research including literature reviews, mechanistic studies, epidemiological investigations, evidence synthesis, and animal model research examining potential carcinogenic exposures.
How competitive is this grant?
NIH R01 grants are highly competitive. Success rates typically range from 20-30%. Strong preliminary data, clear innovation, and strong institutional support improve competitiveness.
What is the typical funding range?
R01 grants typically award $250,000-$500,000 per year for 3-5 years, though this varies by field. The total project period budget depends on your research scope and institutional guidelines.
💡 Tips for applicants
- Ground your application in published literature: This program values systematic hazard assessment. Build your proposal on strong evidence syntheses and cite recent, peer-reviewed research extensively.
- Clearly distinguish from clinical work: If your background includes clinical research, explicitly explain why this study is non-clinical and what mechanistic or epidemiological insights it provides.
- Include preliminary data: NIH reviewers expect evidence of feasibility. If assessing a particular substance or exposure, provide preliminary analysis demonstrating your methodology and access to relevant datasets.
- Address alternative explanations: Anticipate and address confounding factors, publication bias, and other limitations in the evidence base you're examining.
- Partner strategically: Collaborate with experts in toxicology, epidemiology, or relevant disease areas to strengthen your team and increase reviewer confidence in your hazard assessment approach.
⚠️ Common mistakes
Applications often fail when they include clinical trial components despite the explicit "clinical trial not allowed" restriction—reviewers immediately screen these out. Another common issue is weak evidence synthesis; applicants sometimes propose hazard assessment without rigorous systematic review methodology or clear prioritization criteria. Finally, many applications underestimate the time required for comprehensive literature analysis and hazard characterization, resulting in unrealistic project timelines or insufficient methodological detail.
Similar grants
- OPEN 27-0343-10 FFY27 Local Agency General Non-Enforcement — Illinois Department of Transportation
- ROLLING Annual Agency Threshold Application Applicants for Funding Start Here — Texas City of Austin - Austin Public Health
- CLOSED Virginia’s Black Indigenous and People of Color (BIPOC) Grant – FY26 — Virginia The Virginia Department of Historic Resources
- ROLLING RTAP Grant Program (Rolling) — Virginia Department of Rail and Public Transportation
- ROLLING Rail Industrial Access Grant (RIA) — Virginia Department of Rail and Public Transportation